Patent intelligence · US
US 10966931
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
Patent details — US 10966931
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 6, 2021
- Expiration
- Apr 1, 2041
- Applicant
- Jazz Pharmaceuticals, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/19, A61K9/2054, A61K9/209
Quick answer
US 10966931 (Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Apr 6, 2021. Expires Apr 1, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Jazz Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/19, A61K9/2054, A61K9/209, A61K9/2833, A61K9/284
More from Jazz Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427160
Use of cannabinoids in the treatment of epilepsy
granted -
US 12403136
Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof
granted -
US 12396963
Cannabidiol-type cannabinoid compound
granted -
US 12383512
Cannabidiol-type cannabinoid compound
granted -
US 12383567
Use of cannabinoids in the treatment of epilepsy
granted -
US 12364670
Cannabidiol-type cannabinoid compound
granted -
US 12357586
Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
granted -
US 12350253
Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease
granted
Frequently asked questions
What is US patent 10966931?
US 10966931 (Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances) is held by Jazz Pharmaceuticals, Inc.. Status: granted. Granted Apr 6, 2021. Expires Apr 1, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10966931?
Jazz Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.
When does US 10966931 expire?
Our index shows an expiration date of Apr 1, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.